Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Lise
Contact Lise, search articles and posts on X, monitor coverage, and track replies from one place.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
ArticleVolume 44, Issue 7p1418-1436.e12Open access Affiliations & Notes 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, United States of America 2Department of Medicine, Brigham and Women’s Hospital, Boston, MA, 02115, United States of America 3Department of Medicine, Harvard Medical School, Boston, MA, 02115, United States of America 4Institute for Precision Medicine, University of Pittsburgh, Pittsburgh, PA, 15260, United States of America 5Department of...
ArticleOnline nowOpen access Affiliations & Notes 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA 2Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02115, USA 3Department of Medicine, Harvard Medical School, Boston, MA 02115, USA 4Institute for Precision Medicine, University of Pittsburgh, Pittsburgh, PA 15260, USA 5Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA 6Department of Immunology,...
Abstract Immune checkpoint inhibition (ICI) benefits only a subset of patients with metastatic triple-negative breast cancer and determinants of response remain unclear. We assembled a longitudinal cohort of 103 female patients from the phase 2 TONIC trial, with samples spanning primary tumors, pretreatment metastases and on-treatment metastases during nivolumab therapy.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
